hyaluronic acid + chondroitin sulphate + magnesium trisilicate

This is an **oral combination formulation** comprising **hyaluronic acid**, **chondroitin sulphate**, and **magnesium trisilicate**. The combination is designed primarily for the management of **gastroesophageal reflux disease (GERD)**, particularly in patients unresponsive to standard proton pump inhibitor therapy. - **Hyaluronic acid** and **chondroitin sulphate** are glycosaminoglycans that together form a bioadhesive, protective barrier over mucosal surfaces, reducing reflux symptoms and supporting mucosal healing. - **Magnesium trisilicate** acts as an antacid, neutralizing gastric acid and protecting the esophageal mucosa. - Mechanistically, the combination provides rapid, symptomatic relief from heartburn and acid regurgitation, with onset of action within 30–40 minutes, often lasting several hours. - The formulation is available as chewable, suckable, or melt-in-mouth tablets to optimize local mucosal action. - This preparation is generally well tolerated; adverse effects are most commonly mild gastrointestinal complaints. - The combination is under investigation and marketed as a medical device and dietary supplement in some regions, not as a classical pharmaceutical drug. - Therapeutic effects for osteoarthritis and related inflammatory conditions by hyaluronic acid and chondroitin sulphate have also been described, but are not the primary indication for magnesium trisilicate combinations[1][3][7].